Toxic Epidermal Necrolysis in a Patient with Allopurinol, Colchicine and Alcohol Use

Year 2020, Volume: 11 Issue: 3, 65 - 67, 23.11.2020

Munise Daye Selami Aykut Temiz , Şevket Arslan , Alper Yosunkaya , Selim Gümüş Orkun Uyanık Hayri Ahmet Burak Nurşen

https://doi.org/10.33706/jemcr.684184

Abstract

Introduction: Toxic epidermal necrolysis is a severe, acute, mucocutaneous, life-threatening hypersensitivity syndrome with high mortality and bullous lesions on the skin, eyes and mucous membranes. It often develops due to drugs. Sulfonamide group antibiotics and antiepileptic drugs are the most commonly responsible agents. Allopurinol is a common cause of toxic epidermal necrolysis as in most drug reactions. Colchicine is widely used in dermatology and rheumatology and is generally known as an agent with a broad safety profile.
Case: Here we present a case of toxic epidermal necrolysis in our case with allopurinol, colchicine and alcohol use in order to draw attention to the increased risk of drug coexistence.
Conclusion: Again, we wanted to draw attention to the management of our case and the efficacy and safety of high-dose intravenous immunoglobulin therapy.

Keywords

Toxic epidermal necrolysis, allopurinol, colchicine, intravenous immunoglobulin

References

• 1. Chaby G, Ingen-Housz-Oro S, De Prost N, et al. Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: Prevalence and patients' characteristics. Journal of the American Academy of Dermatology 2019; 80(5), 1453-1455.
• 2. Rodríguez-Martín S, Martín-Merino E, Lerma V, et al. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. European journal of clinical pharmacology 2019; 75(2), 237-246.
• 3. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. Journal of Investigative Dermatology 2008; 128(1), 35-44.
• 4. Anzengruber F, Graf V, Hafner J, Meienberer N, Guenova E, Dummer R. Efficacy and safety of Colchicine in inflammatory skin diseases: a retrospective, monocentric study in a large tertiary center. Journal of Dermatological Treatment (just-accepted) 2019, 1-25.
• 5. Schneider JA, Cohen PR. Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Advances in Therapy, 2017; 34(6), 1235-1244.
• 6. Aykut TS, Recep D, Munise D, Arzu A, İlkay Ö. A Case of Bupropion-Induced Toxic Epidermal Necrolysis (TEN). Ann Clin Case Rep. 2017; 2, 1396.
• 7. Alpsoy E, Dicle Ö, Karakas AA. Steven-Johnson sendromu ve toksik epidermal nekroliz/Steven-Johnson syndrome (SJS) and toxic epidermal necrolysis. Turkderm 2010; 44(4), 180-186.
• 8. Lee HY, Lim YL, Thirumoorthy T, Pang SM. The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre. British Journal of Dermatology 2013; 169(6), 1304-1309.
• 9. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta‐analysis. British Journal of Dermatology 2012; 167(2), 424-432.
• 10. Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of S tevens–J ohnson syndrome and toxic epidermal necrolysis: a meta‐analysis with meta‐regression of observational studies. International journal of dermatology 2015; 54(1), 108-115.
• 11. Yu KH, Yu CY, Fang YF. Diagnostic utility of HLA‐B* 5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta‐analysis. International journal of rheumatic diseases 2017; 20(9), 1057-1071.
• 12. Chaby G, Ingen-Housz-Oro S, De Prost N, Wolkenstein P, Chosidow O, Fardet L. Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: Prevalence and patients' characteristics. Journal of the American Academy of Dermatology 2019; 80(5), 1453-1455.
• 13. Konda C, Rao AG. Colchicine in dermatology. Indian Journal of Dermatology, Venereology, and Leprology 2010; 76(2), 201.